Boston Scientific Bolt Medical acquisition ‘checks right boxes,’ JPMorgan says

JPMorgan keeps an Overweight rating on Boston Scientific (BSX) with a $110 price target after the company announced an agreement to acquire the 74% stake of Bolt Medical not yet owned for $443M upfront. The firm noted that it was not surprised to see Boston Scientific complete its ownership stake, citing expressed interest in the intravascular lithotripsy market. The analyst told investors in a research note that with a large, high-growth market opportunity in intravascular lithotripsy complementary to Boston Scientific’s existing solutions in interventional cardiology, the firm thinks the deal checks a lot of the right boxes for the company and should be nicely accretive to growth once launched.